---
title: FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable
  for human hematopoietic stem cells
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39841016/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250123170657&v=2.18.0.post9+e462414
source: Blood
description: Leukemic stem cells (LSCs) fuel acute myeloid leukemia (AML) growth and
  relapse, but therapies tailored towards eradicating LSCs without harming normal
  hematopoietic stem cells (HSCs) are lacking. FLT3 is considered an important therapeutic
  target due to frequent mutation in AML and association with relapse. However, there
  has been limited clinical success with FLT3 drug targeting, suggesting either that
  FLT3 is not a vulnerability in LSC, or that more potent inhibition is required,
  a ...
disable_comments: true
---
Leukemic stem cells (LSCs) fuel acute myeloid leukemia (AML) growth and relapse, but therapies tailored towards eradicating LSCs without harming normal hematopoietic stem cells (HSCs) are lacking. FLT3 is considered an important therapeutic target due to frequent mutation in AML and association with relapse. However, there has been limited clinical success with FLT3 drug targeting, suggesting either that FLT3 is not a vulnerability in LSC, or that more potent inhibition is required, a ...